| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
16,182 |
15,764 |
$813K |
| 87635 |
Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe |
8,463 |
8,231 |
$421K |
| 87502 |
Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets |
4,011 |
3,938 |
$316K |
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
3,730 |
3,643 |
$263K |
| 87651 |
Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe |
6,586 |
6,417 |
$189K |
| 99203 |
Office or other outpatient visit for the evaluation and management of a new patient, low complexity |
1,684 |
1,647 |
$128K |
| 87634 |
|
248 |
241 |
$12K |
| 71046 |
Radiologic examination, chest; 2 views |
493 |
490 |
$8K |
| 99202 |
Office or other outpatient visit for the evaluation and management of a new patient, straightforward |
24 |
24 |
$1K |
| 74018 |
|
56 |
56 |
$896.32 |
| 81003 |
|
290 |
285 |
$544.28 |
| 99212 |
Office or other outpatient visit for the evaluation and management of an established patient, straightforward |
12 |
12 |
$397.13 |
| J1100 |
Injection, dexamethasone sodium phosphate, 1 mg |
209 |
206 |
$117.26 |
| J7611 |
Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, concentrated form, 1 mg |
53 |
33 |
$13.51 |
| J7644 |
Ipratropium bromide, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose form, per milligram |
44 |
28 |
$7.35 |